Article
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.
Leukemia - 1 Dec 2019
Singhal Deepak, Wee Li Yan A, Kutyna Monika M, Chhetri Rakchha, Geoghegan Joel, Schreiber Andreas W, Feng Jinghua, Wang Paul P-S, Babic Milena, Parker Wendy T, Hiwase Smita, Edwards Suzanne, Moore Sarah, Branford Susan, Kuzmanovic Teodora, Singhal Nimit, Gowda Raghu, Brown Anna L, Arts Peer, To Luen B, Bardy Peter G, Lewis Ian D, D'Andrea Richard J, Maciejewski Jaroslaw P, Scott Hamish S, Hahn Christopher N, Hiwase Devendra K
Abstract excerpt
Therapy-related myeloid neoplasms (T-MN) are poorly characterized secondary hematological malignancies following chemotherapy/radiotherapy exposure. We compared the clinical and mutational characteristics of T-MN (n = 129) and primary myelodysplastic syndrome (P-MDS, n = 108) patients. Although the somatic mutation frequency was similar between T-MN and P-MDS patients (93% in both groups), the pattern was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.